A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin Injection in Healthy Adult Volunteers

Trial Profile

A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin Injection in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Octreotide (Primary) ; Octreotide
  • Indications Acromegaly; Chemically-induced disorders; Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Dauntless Pharmaceuticals
  • Most Recent Events

    • 20 Mar 2018 Results assessing pharmacokinetics, pharmacodynamics, safety, and tolerability of intranasal formulation of DP1038 compared to FDA-approved subcutaneous injection of octreotide acetate, presented at The 100th Annual Meeting of the Endocrine Society.
    • 24 Oct 2017 According to a Dauntless Pharmaceuticals media release, results from this trial will be presented at the annual North American Neuroendocrine Tumor Society (NANETS) Symposium.
    • 11 May 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top